Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEBDOX transarterial chemoembolization for breast cancer liver metastases
NL-OMON37702Phase 2Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in breast cancer and hepatic metastasis, sponsored by Netherlands Cancer Institute. Primary endpoints: Technical feasibility of the treatment protocol, Proportion of patients completing scheduled treatment plan and 1 more. Planned start Oct 2012; status: not yet recruiting.
02
Drugs
doxorubicin
03
Conditions
breast cancerhepatic metastasis
Beyond the preview
Go deeper on NL-OMON37702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37702.